Recent REPROCELL News

REPROCELL News

The REPROCELL group has signed a non-exclusive distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand.

Continue reading →


Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF). 

Continue reading →


Yokohama, Japan, & San Carlos, California, USA — REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship.

Although NeuCyte has direct sales in North America, this new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements. These components come in kit formats so the user can set up well-defined, highly functional in vitro co-culture systems for compound screening, disease modeling and neurotoxicity assessment.

Continue reading →


Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.

Continue reading →


The lab-scale system will allow researchers to study and culture stem cells in suspension

Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.

We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.

Continue reading →


Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders. The suite has been designed to support Clinical Trials of cell therapy products.

Continue reading →


REPROCELL India (formerly BioServe Biotechnologies India Pvt Ltd) and Hanugen Therapeutics have announced the launch of their custom manufacture offering for synthesis of milli molar scale clinical grade oligonucleotides for gene therapy.

Continue reading →


Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.

Continue reading →


  • The collaboration is part of Medicines Discovery Catapult’s Virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour.
  • The collaboration is part of Medicines Discovery Catapult’s Virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour

Glasgow UK, 12 March 2019 – REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.

Continue reading →


Recent REPROCELL News